CancerLife: Patient-Driven Solution in Cancer Care

NCT03371147 | Completed

• 1 other identifier: JWCI-17-1001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The primary purpose of this study is to evaluate the use of a digital information and communication platform (DICP) in improving outcomes in patients with cancer and their caregivers.

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

• Self-Reported Symptoms

  Reduction in severity and occurrence of symptoms

  2 years

Secondary Outcomes (6)

• Quality of Life (QOL)

  2 years

• Anxiety

  2 years

• Depression

  2 years

• Emotional state

  2 years

• Quality of Physician-Patient Interaction

  2 years

Study Arms (2)

CancerLife

EXPERIMENTAL

Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.

Other: CancerLife

Usual care

NO INTERVENTION

Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.

Interventions

CancerLife OTHER

CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team.

CancerLife

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \> 18 years
• Diagnosis of cancer
• Receiving systemic treatment (chemotherapy, biotherapy/immunotherapy, hormonal therapy) that is expected to continue for at least 3 treatment sessions (approximately 9 weeks) from the time of enrollment
• Karnofsky Index ≥50%
• Able to understand and sign informed consent
• Owns and able to use an electronic communication device (smart phone, tablet, laptop, desktop) and answer simple self-report questionnaires on their own

You may not qualify if:

• Relevant cognitive impairment
• Participating in a therapeutic clinical trial
• Unable to read and comprehend English language text

Sponsors & Collaborators

• Saint John's Cancer Institute: lead
• Healthy Platforms, LLC: collaborator

Study Sites (1)

John Wayne Cancer Institute at Providence Saint John's Health Center

Santa Monica, California, 90404, United States

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

• Santosh Kesari, MD PhD

  Saint John's Cancer Institute

  STUDY CHAIR

• Marlon G Saria, PhD RN FAAN

  John Wayne Cancer Institute at Providence Saint John's Health Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2017
• First Posted: December 13, 2017
• Study Start: March 15, 2018
• Primary Completion: January 7, 2020
• Study Completion: January 7, 2020
• Last Updated: February 9, 2021

Record last verified: 2021-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)